Prostate Cell News Volume 17.13 | Jul 24 2026

    0
    26







    2026-07-24 | PCN 17.13


    Prostate Cell News by STEMCELL Technologies
    Vol. 17.13 – 24 July, 2026

    TOP STORY

    A Ligandable PNT Domain Establishes ERG As a Directly Targetable Oncogenic Driver in Prostate Cancer

    Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article
    Cartoon visual of a scientist at a laptop partaking in science communication to represent a plain language guide for life scientists.
    PUBLICATIONSListed by the impact factor of the journal

    ZNF263-NuRD-Mediated Repression of STAT1 Curtails MHC-I Antigen Presentation and IFN-γ Efficacy in Prostate Cancer

    Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Randomized Phase II Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: The CheckPRO, CA209-8TY Trial

    Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.
    [Journal for Immunotherapy of Cancer]

    Full Article

    A Novel lncRNA HUDRPC Suppresses Ferroptosis via the DDX5/DDIT3 Pathway to Promote Docetaxel Resistance in Prostate Cancer

    The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.
    [Cancer Letters]

    Abstract

    Adipose Triglyceride Lipase Driven Lipolysis As a Targetable Metabolic Vulnerability in Prostate Cancer with Intrinsic Metabolic Inflexibility

    ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.
    [British Journal of Cancer]

    Full Article

    METTL5-Mediated rRNA Modification Controls Prostate Cancer Progression through the IRF7/DNA2 Axis and Mitophagy Regulation

    Researchers showed that the rRNA m6A methyltransferase METTL5 was progressively upregulated during prostate cancer progression and was associated with poor patient survival.
    [Oncogene]

    Abstract

    Targeting the NR3C1-ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

    Scientists revealed that the nuclear receptor subfamily 3 group C member 1 (NR3C1)-acyl-CoA synthetase long-chain family member 4 (ACSL4) axis regulates lipid peroxidation and promotes radioresistance.
    [Cancer Science]

    Full Article
    Scientists discussing a journal around a table at a journal club.
    REVIEWS

    Development and Advantages of O-(Carboxymethyl)-L-Tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer

    The authors highlight that PSMA-targeting agents incorporate the O-(carboxymethyl)-L-tyrosine scaffold, a versatile linker that enhances binding affinity and optimizes pharmacokinetics.
    [Journal of Medicinal Chemistry]

    Abstract
    Graphical Abstract
    INDUSTRY AND POLICY NEWS

    FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

    Pfizer, Inc. announced that the US FDA accepted for Priority Review a supplemental New Drug Application for TALZENNA®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI®, an androgen receptor pathway inhibitor, for homologous recombination repair gene-altered mCSPC.
    [Pfizer, Inc.]

    Press Release
    FEATURED EVENT

    11th CAR-TCR Summit

    September 15-17, 2026
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Associate – Prostate Cancer Screening

    University of Cambridge – Cambridge, England, United Kingdom

    Faculty Positions – Cancer Research

    Thomas Jefferson University – Philadelphia, Pennsylvania, United States

    Postdoctoral Fellow – Immunotherapy in Prostate Cancer

    University of Louisville – Louisville, Kentucky, United States

    Postdoctoral Fellow – Cancer Prevention Fellowship Program

    CICF International, Inc. – Maryland, United States

    Postdoctoral Program – Integrated Science Lab

    UmeÃ¥ University – UmeÃ¥, Sweden

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2